NEW YORK CITY, NY / ACCESS Newswire / September 24, 2026 / Pomerantz LLP is investigating claims on behalf of investors of Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
The investigation concerns whether Anavex and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On March 25, 2026, Anavex issued a press release "announc[ing] that it has withdrawn its application for the marketing authorization of blarcamesine in the EU as an add-on therapy for the treatment of early Alzheimer's disease in adults, which had been under review by the European Medicines Agency (EMA)." The press release said that "[t]he decision to withdraw the application follows feedback from the EMA's Committee for Medicinal Products for Human Use (CHMP) indicating that it would not be in a position to issue a positive opinion for the application at this time."
On this news, Anavex's stock price fell $1.45 per share, or 34.61%, to close at $2.74 per share on March 25, 2026.
Then, on May 6, 2026, Anavex reported that a special committee of the Company's board of directors had "terminated the employment of Christopher Missling, PhD as the Company's Chief Executive Officer for Cause," to be "effective immediately, for, among other things, conduct that the Special Committee believed was inconsistent with Company policy."
On this news, Anavex's stock price fell $0.22 per share, or 6.59%, to clos at $3.12 per share on May 7, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: Pomerantz LLP
View the original press release on ACCESS Newswire
COMTEX_493235055/2457/2026-09-24T17:27:04